932 results on '"Kukreti, Vishal"'
Search Results
52. Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience
53. Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume
54. Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size
55. Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma
56. Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma
57. Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation
58. Recovery of a quality improvement project during the COVID pandemic.
59. Implementation and impact of Choosing Wisely recommendations in oncology: A scoping review.
60. Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis
61. Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults
62. Primary Marginal Zone Lymphoma of the Subcutis Associated With Panniculitis and Fat Necrosis
63. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
64. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma
65. Age 40 Years and Under Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant
66. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma
67. A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma
68. Clinical utility of interim CT scans in patients receiving bendamustine and rituximab for first line treatment of follicular lymphoma.
69. Evolving Best Practice for Take-Home Cancer Drugs
70. Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia
71. Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution
72. Tandem Transplantation in Myeloma Patients with High Risk Cytogenetics: A 10 Year Single-Centre Experience
73. The impact of lenalidomide maintenance on second‐line chemotherapy in transplant eligible patients with multiple myeloma
74. Five biopsies, one diagnosis: challenges in idiopathic multicentric Castleman disease
75. A Case of Rapid Deterioration with Marked Hypergammaglobulinemia
76. The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database
77. Improving medication reconciliation in ambulatory cancer care.
78. Current state assessment of the organization and delivery of systemic treatment in Ontario.
79. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents
80. D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma
81. Efficacy of thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
82. From T-antigen to plasmalogen-derived aldehydes: the identification of a marker of colorectal cancer in human rectal mucous
83. Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis.
84. Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains.
85. Autologous stem cell transplant for light chain deposition disease: Incorporating bortezomib to the induction therapy
86. Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation
87. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients
88. Syngeneic transplants for multiple myeloma – a single center experience and review of the literature
89. Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma
90. Feasibility randomised controlled trial of remote symptom chemotherapy toxicity monitoring using the Canadian adapted Advanced Symptom Management System (ASyMS-Can): a study protocol
91. An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment – validation of official dosing guidelines
92. Evaluation of Lymphadenopathy and Suspected Lymphoma in a Lymphoma Rapid Diagnosis Clinic
93. Two distinct syndromes of lymphoma associated AL amyloidosis: A case series and review of the literature
94. Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study
95. The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of Overall Survival
96. Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma
97. Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation
98. Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?
99. Development and Validation of a Score to Predict Acute Care Use After Initiation of Systemic Therapy for Cancer
100. The Impact of Lenalidomide Maintenance on Second Line Chemotherapy in Transplant Eligible Patients with Multiple Myeloma in the Canadian Setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.